Introduction {#s01}
============

Among males and females across the world, gastric cancer is the fourth and fifth most common malignant tumor and the third and fifth leading cause of cancer-related death, respectively ([@b1]), while in China, it is the second most common cancer and the third leading cause of cancer death ([@b2]). The high mortality rate is partially because of late diagnosis at locally advanced stages ([@b3]). Therefore, many attempts have been made to improve patients' survival, such as tailoring the extent of surgery and adopting neoadjuvant and/or adjuvant therapy. Previous studies have indicated that perioperative radio-chemotherapy or chemotherapy regimens had more favorable effects on increasing curative resection rates, disease-free survival, and overall survival ([@b3]-[@b9]). As a result, the standard treatment for patients with locally advanced gastric cancer no longer relies on surgery alone but also on perioperative radio-chemotherapy or chemotherapy since the 2000s ([@b10]).

For patients with locally advanced gastric cancer, perioperative radio-chemotherapy or chemotherapy can improve the overall and progression-free survival, but the rate of good response (GR) to neoadjuvant therapy varies between 30% and 80%, depending on which evaluation methods are used ([@b3]-[@b9]). This means that at least 20% of the patients receiving neoadjuvant therapy cannot benefit from perioperative radio-chemotherapy or chemotherapy, and are described as non-good response (non-GR). For these patients, neoadjuvant therapy not only increases the cost of medical care, but also weakens their immune system and delays surgery. Therefore, it is important that radiologists provide accurate information to physicians by identifying non-GR by non-invasive approaches so that alternative treatment, such as direct surgery can be adopted. Therefore, it is necessary to develop a predictive indicator or model for the treatment response to neoadjuvant therapy for gastric cancer, which offers guidance on whether performing neoadjuvant chemotherapy is necessary to avoid additional toxicity, improve patients' quality of life, and reduce unnecessary morbidity and cost.

Previous studies have highlighted several indicators and their correlations to the treatment response for locally advanced gastric cancer, including peripheral venous blood neutrophil-to-lymphocyte ratio (NLR), C-reactive protein and albumin levels, modified Glasgow prognostic score (mGPS) and computed tomography (CT) perfusion ([@b11]-[@b13]). However, the majority of the previous works focusing on the correlations did not clearly describe the predictive value of the indicators, with the excepting of CT perfusion. Due to the moderate sensitivity (69%) and specificity (58%) of a cut-off value of \>25% reduction in tumor permeability for predicting the clinical response of preoperative chemotherapy, CT perfusion is insufficient to support a clinical decision ( [@b13]).

Radiomics -- the high-throughput extraction of quantitative imaging features characterizing the spatial relationships and consistency of signal intensities -- within the tumor region has demonstrated the ability to predict treatment response across a range of cancer types and imaging modalities ([@b14]). In the realm of gastric cancer, radiomics of CT has been verified as a potential preoperative prognostic biomarker in gastric cancer ([@b15]); pre-treatment CT texture analysis can potentially provide important information regarding the response rate to neoadjuvant therapy for gastric cancer, thereby improving risk stratification ([@b16]). Therefore, radiomics may be used as a crucial marker for the response to neoadjuvant therapy in locally advanced gastric cancer.

In this study, we investigated the ability of the radiomics of pre-treatment CT for prediction of non-GR in locally advanced gastric cancer with preoperative chemotherapy using 32 combinations of four feature-selection methods and eight classifier models.

Materials and methods {#s02}
=====================

This is a single-center, retrospective study that follows the Declaration of Helsinki and good clinical practice guidelines, and was approved by the Ethics Committee of the Yunnan Cancer Hospital, Kunming, China. The committee waived the need for informed consent to be obtained because this case series is a retrospective study, and patients could not be contacted after discharge from hospital. The medical records and data accessed in the study contained no personal or identifying information.

Patients {#s02.01}
--------

Forty-seven consecutive patients with CT-staged II/III gastric cancer treated with neoadjuvant chemotherapy between December 2014 and March 2017 were enrolled. As recommended to the literature ([@b17]), the inclusion criteria were as follows: 1) histologically proven adenocarcinoma of the stomach with the following diagnosis: (a) stage IIA−IIIC, i.e., T3−T4 and/or N+, according to the American Joint Committee on Cancer (AJCC) 8th edition ([@b18]), and (b) considered operable following initial staging investigations (surgeon believes that an R0 resection can be achieved); 2) aged 18 years or older; 3) Eastern Cooperative Oncology Group (ECOG) performance status 0−1; 4) adequate organ function defined as follows: Bone marrow, hemoglobin ≥90 g/L, absolute neutrophil count (ANC) ≥1.5×10^9^/L, white blood cell count ≥3×10^9^/L, platelet count ≥100×10^9^/L. Hepatic function, serum bilirubin ≤1.5× upper limit of normal value (ULN), aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤3.0×ULN. Renal function, serum creatinine ≤0.150 mmol/L, and calculated creatinine clearance ≥50 mL/min; and 5) patients with a history of ischemic heart disease and abnormal electrocardiograph (ECG), or who were over 60 years of age were required to undergo a pre-treatment evaluation of cardiac function with a multiple-gated acquisition (MUGA) scan or echocardiogram and a left ventricular ejection fraction ≥50%. Exclusion criteria were as follows: 1) patients who refused surgery (n=8); 2) patients with peritoneal carcinosis confirmed by surgery and pathological evidence (n=2); 3) patients with serious complications, such as intestinal obstruction, active bleeding, enterobrosis, or obvious infections (n=4); or 4) patients with poor clinical conditions, such as deterioration before chemotherapy started (one), the necessity for immediate surgery due to other disease (one), and worsening coexisting disease (one) (n=3).

CT protocols {#s02.02}
------------

The CT examination was performed with a 128-slice CT scanner (SOMATOM Definition AS+, Siemens Medical Solutions, Forchheim, Germany).

Before the examination, patients received 400−600 mL water orally to distend the stomach. A nonionic contrast agent (Ultravist 300, Bayer Schering Pharma AG, Berlin, Germany) was injected with antecubital venous access at a rate of 3.5 mL/s. A total of 80−100 mL (1.5 mL per kg of body weight) was injected with a CT-compatible power injector (Bracco ACIST EZEM, EmpowerCTA) followed by a 20-mL saline flush at the same rate.

The CT scanning parameters were 64 detector rows; beam collimation 128×0.6 mm; pitch 0.6; 0.5 s/rotation; kVp/effective mA 120/200; display field of view (DFOV) 42 cm^2^; 512×512 matrix; slice thickness 1 mm; gap 1 mm.

As recommended by the literature ([@b19]), unenhanced, late arterial phase (AP, 40 s after injection) and portal venous phase (PP, 70 s after injection) of the upper abdomen scans were acquired for all patients.

Treatment protocols {#s02.03}
-------------------

The treatment protocol followed the National Comprehensive Cancer Network (NCCN) guidelines ([@b20]). Neoadjuvant chemotherapy was administered preoperatively for three cycles. Each 3-week cycle consisted of epirubicin (50 mg per m^2^ of body-surface area) by intravenous bolus on d 1, oxaliplatin (130 mg/m^2^) was administered by intravenous infusion in 500 mL of 5% glucose over a period of 2 h on d 1, and capecitabine (1,250 mg/m^2^, twice daily) from d 1 to d 21.

Treatment response evaluation {#s02.04}
-----------------------------

The pathological staging served as the reference standard and was determined according to the tumor-node-metastasis (TNM) classification system recommended by AJCC, eighth edition ([@b18]). The resection specimens were evaluated by a dedicated gastrointestinal pathologist (Reader 1, with 10 years of experience), blinded to the CT data. Patients were separated into different response groups as GR versus non-GR according to the NCCN ([@b20]) and modified tumor regression grade (TRG) based on Ryan's definition ([@b21]). The GR patients included those exhibiting a complete response with no viable cancer cells (TRG 0) and moderate response with only a small cluster or isolated cancer cells remaining (TRG 1). The non-GR included TRG 2: a minimal response with residual cancer remaining but with predominant fibrosis and TRG 3: a poor response with minimal or no tumor death and extensive residue cancer.

Radiomics feature extraction {#s02.05}
----------------------------

All images were reviewed using dedicated software for image analysis (3-D Slicer, Version 4.6) by a single experienced rectal CT radiologist (Reader 2, with 9 years of experience). In the late AP, each gastric tumor was manually outlined as a region of interest (ROI) slice by slice, because this is the effective phase for identifying the mucosal enhancement of early gastric cancers ([@b19]). In the PP, the late AP image was used as a reference. After marking the ROIs to the corresponding images, a volume of interest (VOI) was built. Next, 3-D radiomics features were extracted from the VOI using in-house software built by MATLAB 2013a (Mathworks, Natick, MA, USA). These radiomics features included four groups: 1) first order statistics; 2) shape- and size-based features; 3) texture features; and 4) wavelet features. To extract wavelet features, 53 types of default wavelets built in Matlab were applied to the origin images. In total, 19,985 radiomics features were extracted in AP and PP for each patient.

Radiomics feature selection and radiomics classifier building {#s02.06}
-------------------------------------------------------------

Before selecting features, the redundant features were removed. When the Pearson correlation coefficient of any two features was \>0.90, one of them was selected at random, and the rest could be treated in the same manner ( [@b22]). After that, z-score standardization for standardizing all features was adopted. There were four methods used in feature selection, including recursive features elimination based on random forest (RFE-RF), recursive features elimination based on Naive Bayes (RFE-NB) ([@b23]), selection by a filter based on linear discriminant analysis (SBF-LDA) ([@b24]), and least absolute shrinkage and selection operator (lasso) ([@b25]). The methods selected here were representatives of the three main methods frequently used in feature selection (wrapped, filtered and embedded methods) ([@b26]).

In the process of building the classifier model, eight methods were adopted: RF, linear discriminant analysis (LDA), support vector machines with radial kernel (svmRadial), Linear-SVM (svmLinear), neural networks (nnet), K-nearest neighborhood (KNN), Naive Bayes (NB), lasso. The methods were implemented by R (Version 3.4.0) packages including caret (Version 6.0-76). The Leave-one-out Cross Validation (LOOCV) was used in resampling of training and evaluating models in the area under the receiver operator characteristic (ROC) curve.

Radiomics feature selection and radiomics classifier building of AP and PP were analyzed separately, but based on the same methods (including features' extraction, selection and model building).

Evaluation of radiomics classifier performance {#s02.07}
----------------------------------------------

The feature selection methods and classifier model were all evaluated in one sample (n=30). A combination of the selection and classifications was generated, and a comparison was performed to find a better model. Because only 30 patients were involved, analysis of a single training cohort was applied. To evaluate the model, the average area under the curve (AUC) was used in resampling; meanwhile, accuracy, sensitivity and specificity were also measured based on the training cohort. Since the number of patients was limited, the AP and PP were compared to enhance the conviction of our model, and were analyzed separately using the same methods (features' extraction, selection and model building).

Statistical analysis {#s02.08}
--------------------

The statistical analyses were performed with R software (Version 3.4.0; R Foundation for Statistical Computing, Vienna, Austria) (http://www.R-project.org). $\large\begin{document}$\overline{{x}}{{±}}{{s}}$\end{document}$ is provided for normally distributed variables. Frequencies are provided for categorical data. Individual variables were analyzed for significant differences using a *t*-test and the Mann-Whitney-Wilcoxon test for non-normally distributed parameters. The consistency of different ROC was examined by the DeLong test. A group difference comparison with a two-sided P-value of \<0.05 was considered significant. The following R packages were used for feature selection methods: "caret" (rfe), "randomforest" (rf), "e1071" (nb), "MASS" (LDA), "glmnet" (lasso). The following packages were used for classification methods: "randomforest" (rf), "MASS" (LDA), "kernlab" (svmLinear), "kernlab" (svmRadial), "nnet" (nnet), "class" (knn), "e1071" (nb), "glmnet" (lasso).

Results {#s03}
=======

Patient Characteristics {#s03.01}
-----------------------

A total of 30 patients (aged 59.9±8.9 years) were involved in the study. Among these patients, 36.7% (11/30) were GR (TRG 0−1,*[Figure 1](#Figure1){ref-type="fig"}*) and 63.3% (19/30) were non-GR (TRG 2−3,*[Figure 2](#Figure2){ref-type="fig"}*). The detailed clinical characteristics are listed in *[Table 1](#Table1){ref-type="table"}*. There were no statistical differences between GR versus non-GR groups concerning age, primary tumor site and pre-treatment clinical TNM stage, with the exception of gender (P=0.012) and post-treatment pathological stage (P\<0.001) (*[Table 1](#Table1){ref-type="table"}*).

Predictive performance of radiomics classifier {#s03.02}
----------------------------------------------

The AUC was used to quantify the prognostic performance of different crossed-feature selection and classification methods in predicting non-GR. In the present study, 32 combinations of feature selection and classification methods were examined. The mean AUC, accuracy, sensitivity and specificity of the different cross-combination machine-learning methods in AP and PP are presented in *[Supplementary Table S1](#TableS1){ref-type="table"}*.

The mean AUC ranged from 0.194 to 0.621 in AP, and from 0.455 to 0.722 in PP. The accuracy was within the range of 0.276 to 0.621 in AP, and 0.412 to 0.793 in PP. The sensitivity was in the range of 0.000 to 0.727 in AP, and 0.091 to 0.636 in PP. The range of specificity was 0.389 to 0.667 in AP, and 0.556 to 0.889 in PP.

There was only one cross-combination machine-learning method indicating a relatively higher AUC (\>0.600) in AP, while 12 cross-combination machine-learning methods presented relatively higher AUCs (all \>0.600) in PP.*[Figure 3](#Figure3){ref-type="fig"}* depicts the mean AUC, accuracy, sensitivity and specificity of the above 12 crossed methods in PP.

Interestingly, the feature selection method of SBFLDA + classifier of RF in PP was only one cross-combination machine-learning method, achieving a significantly prognostic performance ([*Supplementary Table S2*](#TableS2){ref-type="table"}). *[Figure 4](#Figure4){ref-type="fig"}* shows the ROC curves for the feature selection method of SBFLDA + classifier of RF, which achieved the highest prognostic performance in PP (AUC, 0.722±0.108; accuracy, 0.793; sensitivity, 0.636; specificity, 0.889; Z=2.039; P=0.041) (*[Figure 4](#Figure4){ref-type="fig"}*).

Discussion {#s04}
==========

The main finding of this study was that the pre-treatment CT-based radiomics classifier was a crucial marker of the response to neoadjuvant therapy in locally advanced gastric cancer. We found that the feature selection method SBFLDA + classifier RF of pre-treatment CT imaging in PP could predict non-GR in locally advanced gastric cancer with preoperative chemotherapy with an AUC of 0.722.

Currently, pathological evaluation of the surgical specimen is the only reliable surrogate marker that correlates with long-term oncological outcome ([@b27]). However, such data are available only after completion of all preoperative treatment and surgery, which therefore cannot be used as guidance for adjusting the therapeutic approach. Accordingly, the development of non-invasive biomarkers which have the potential to provide pre-therapy prediction is essential. Such biomarkers would aid in identifying those patients who are less likely to benefit from the current therapies for alternative treatment or intensive follow-up regimens. Furthermore, the biomarkers would also offer guidance for clinicians to decide whether to perform neoadjuvant chemotherapy, in order to avoid additional toxicity, improve the patients' quality of life and reduce unnecessary morbidity and cost ([@b28]). Therefore, the development of a pre-treatment model which is accurate and predictive of the efficacy of neoadjuvant chemotherapy is important for patients with locally advanced gastric cancers.

Many gastric cancers are well visualized with CT ([@b13],[@b15],[@b19],[@b29]), and CT is a routinely used and easily accessible source of information in clinical oncology ([@b15]). Radiomics is a rapidly growing field that converts medical images into high-dimensional, mineable and quantitative data, with the ultimate goal of generating imaging biomarkers to improve evidence-based support of decisions in clinical practice ([@b30]-[@b33]). Quantitative radiomics has tremendous potential to improve cancer care by enhancing the understanding of tumor physiology and aiding in the implementation of personalized medicine ([@b34]). As a noninvasive and cost-effective method of assessing the tumor in its entirety, radiomics allows for the evaluation of tumor characteristics such as spatial-temporal heterogeneity, which is often considered as an important biomarker in oncology ([@b13],[@b35]). Therefore, it is possible to predict the response to neoadjuvant chemotherapy in locally advanced gastric cancers with CT-based radiomics.

Previous studies have demonstrated the importance of radiomics in the realm of the gastric cancer ([@b36]-[@b38]). Ba-Ssalamah *et al*. ([@b36]) reported that the texture-based lesion classification on arterial-phase scans was highly successful in differentiating between gastric adenocarcinoma and lymphoma, and gastrointestinal stromal tumors and lymphoma, with misclassification rates of 3.1% and 0% respectively. Yoon *et al*. ([@b37]) verified that heterogeneous texture features on CT images were associated with increased survival rates in patients with HER2-positive advanced gastric cancer who received trastuzumab-based treatment. Liu *et al*. ([@b38]) stated that some texture features including mean attenuation, maximum attenuation, all percentiles and mode derived from portal venous CT images correlated significantly with the differentiation degree and Lauren classification of gastric cancers (r, −0.231−−0.324, 0.228−0.321, respectively). In addition, several studies have demonstrated the importance of radiomics in predicting the neoadjuvant therapy outcome for tumors ( [@b16],[@b28],[@b30],[@b39]). Giganti *et al*. ([@b16]) illustrated that the following texture parameters could identify non-responders after preoperative chemo-radiation therapy in locally advanced gastric cancer by multivariate analysis: entropy, range and root mean square, and entropy had an AUC of 0.74 for GR prediction. Cha *et al*. ([@b28]) explained that an AUC ranging from 0.69 to 0.77 was used to predict T0 stage after neoadjuvant chemotherapy by three radiomics models in bladder cancer. Nie *et al*. ([@b30]) reported an AUC of 0.89 of radiomics model for GR prediction after preoperative chemo-radiation therapy in locally advanced rectal cancer. Braman *et al*. ([@b39]) claimed that a combined intratumoral and peritumoral radiomics feature set yielded a maximum AUC of 0.78 within the training set and 0.74 within the independent testing set for pathological-complete-response prediction after neoadjuvant chemotherapy in breast cancer. Our present study also found that the radiomics classifier of pre-treatment CT imaging provided a maximum AUC of 0.722 in PP to predict non-GR according to different combinations of feature selection and classification methods, which is similar to the results of previous studies ([@b16],[@b28],[@b39]), but the figure was lower than that of Nie's study ([@b30]).

Due to the small sample size, 32 cross-combinations of feature selection and classification methods were used to investigate the wealth of radiomics for pre-treatment CT in prediction of non-GR in this study. The four feature selections and eight classification methods used in this analysis were chosen because of their simplicity, efficiency and popularity in the field of machine-learning. In this study, different combinations of feature selection and classifications method were found to exhibit distinctive prognostic performances, and the combination of the SBF-LDA feature selection method and RF classification method indicated higher prognostic performance than the other crossed methods for radiomics-based prediction of the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancers. In other words, SBFLDA is the optimal feature selection method, while RF is the optimal classification method in this study. This possibly results from the advantage of SBFLDA and RF. SBFLDA is most commonly used as a pre-processing step to reduce the dimensionality for pattern-classification. The goal of SBFLDA is to project a dataset onto a lower-dimensional space with good class-separability in order to avoid overfitting and reduce computational costs ([@b40]). RF is a fairly efficient model-free method both in the classification and in representing higher predictive performance in previous studies ([@b41],[@b42]). It is known that RF can identify not only the variables that have a linear effect on the response, but also the nonlinear ones. It has the ability to discover the hidden relationship between the response and the variables ([@b41]).

However, this research does have some limitations.

Firstly, the sample size was small compared to the large number of predictors. Seventeen patients were excluded from our initial population owing to our restrictive criteria, resulting in a small but homogeneous population treated with the same treatment protocol. It should be noted that some studies on radiomics analysis with respect to the response to neoadjuvant therapy have been performed while following different treatment protocols ([@b15],[@b30]). Furthermore, due to the limited sample size, AUC, accuracy, sensitivity and specificity were measured based on the training cohort but not on the testing cohort. To enhance the conviction of our model, LOOCV was used as an internal validation technique in order to avoid overfitting.

Secondly, the radiomics parameter was analyzed by the only one type of voxel size. However, the stability of the radiomics parameter may be related to the voxel size. In the future, different voxel sizes should be used to improve the accuracy of quantitative analysis.

Thirdly, no pharmacological precautions were taken such as hyoscine butylbromide or similar drugs to avoid stomach movements, and the water distention technique was used rather than the gas distention technique, which is superior in lesions detection. The CT images of all patients were reviewed carefully and respectively to avoid significant image misalignments.

Conclusions {#s05}
===========

As a pilot study, our results provide initial evidence that it is possible to predict non-GR after neoadjuvant chemotherapy in locally advanced gastric cancers based on the radiomics of CT. Radiomics may represent a promising and non-invasive prognostic tool for the response to neoadjuvant chemotherapy in locally advanced gastric cancers, and it deserves further study.
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![Computed tomography (CT) images of one male patient, at 53 years old with gastric cancer at the stage of cT3N+M0, tumor regression grade 0 (TRG 0) after neoadjuvant chemotherapy, pre-treatment. (A) Late arterial phase image; (B) Portal venous phase image.](cjcr-30-4-406-1){#Figure1}

![Computed tomography (CT) images of one male patient, at 57 years old with gastric cancer at the stage of cT4aN+M0, tumor regression grade 3 (TRG 3) after neoadjuvant chemotherapy, pre-treatment. (A) Late arterial phase image; (B) Portal venous phase image.](cjcr-30-4-406-2){#Figure2}

![Histogram depicting the prognostic performance \[area under the curve (AUC), accuracy, sensitivity and specificity\] of the 12 crossed methods in portal venous phase (PP). It can be observed that feature selection method of selection by a filter based on linear discriminant analysis (SBFLDA) + classifier of random forest (RF) achieved the highest prognostic performance in PP.](cjcr-30-4-406-3){#Figure3}

![Receiver operating characteristic (ROC) curves of the combinations of selection by a filter based on linear discriminant analysis (SBFLDA) + random forest (RF) in predicting non-good response (non-GR) in portal venous phase (PP).](cjcr-30-4-406-4){#Figure4}

###### 

Demographic and clinical characteristics of 30 patients with gastric cancer

  --------------------------------------------------------------------------------------------------------
  Variables                                                                 GR\        non-GR\     P
                                                                            (n=11)     (n=19)      
  ------------------------------------------------------------------------- ---------- ----------- -------
  Male: female                                                              11:0       11:8        0.012

  $\large\begin{document}$\overline{{x}}{{±}}{{s}}$\end{document}$ (year)   57.8±7.2   56.6±10.7   0.197

  Primary tumor site                                                                               0.494

  　Fundus of stomach                                                       1          2           

  　Body of stomach                                                         3          2           

  　Antrum of stomach                                                       7          15          

  Pre-treatment clinical stage                                                                     0.733

  　cT3N0                                                                   1          1           

  　cT3N+                                                                   4          6           

  　cT4N0                                                                   0          1           

  　cT4N+                                                                   6          11          

  Post-treatment pathological stage                                                    \<0.001     

  　pT0N0                                                                   9          0           

  　pT0N+                                                                   0          1           

  　pT1N0                                                                   1          1           

  　pT2N0                                                                   0          1           

  　pT2N+                                                                   0          2           

  　pT3N0                                                                   0          2           

  　pT3N+                                                                   0          3           

  　pT4N0                                                                   1          3           

  　pT4N+                                                                   0          6           
  --------------------------------------------------------------------------------------------------------

###### 

Mean AUC, accuracy, sensitivity and specificity of all cross-combination statistical methods

  Cross-combination statistical methods   Late arterial phase            Portal venous phase                                                     
  --------------------------------------- ---------------------- ------- --------------------- ------- -- ---------------------- ------- ------- -------
  RFERF-lda                               0.338 (0.139--0.537)   0.345   0.273                 0.389      0.540 (0.291--0.789)   0.552   0.182   0.778
  RFERF-RF                                0.293 (0.103--0.482)   0.414   0.091                 0.611      0.566 (0.340--0.791)   0.552   0.273   0.722
  RFERF-svmLinear                         0.348 (0.150--0.546)   0.345   0.182                 0.444      0.586 (0.368--0.803)   0.517   0.091   0.778
  RFERF-svmRadial                         0.409 (0.204--0.613)   0.414   0.182                 0.556      0.626 (0.411--0.841)   0.552   0.091   0.833
  RFERF-nnet                              0.354 (0.148--0.558)   0.379   0.273                 0.444      0.606 (0.387--0.824)   0.483   0.091   0.722
  RFERF-nb                                0.263 (0.079--0.446)   0.310   0.091                 0.444      0.611 (0.341--0.880)   0.483   0.364   0.556
  RFERF-knn                               0.386 (0.161--0.611)   0.379   0.273                 0.444      0.593 (0.384--0.802)   0.414   0.182   0.556
  RFERF-lasso                             0.394 (0.174--0.613)   0.379   0.364                 0.389      0.576 (0.353--0.797)   0.483   0.091   0.722
  RFENB-lda                               0.404 (0.191--0.616)   0.414   0.091                 0.611      0.631 (0.394--0.868)   0.621   0.636   0.611
  RFENB-RF                                0.194 (0.045--0.343)   0.276   0.000                 0.444      0.609 (0.388--0.829)   0.586   0.273   0.778
  RFENB-svmLinear                         0.242 (0.067--0.416)   0.379   0.000                 0.611      0.591 (0.382--0.801)   0.412   0.179   0.557
  RFENB-svmRadial                         0.263 (0.083--0.441)   0.414   0.000                 0.667      0.586 (0.356--0.815)   0.552   0.091   0.833
  RFENB-nnet                              0.354 (0.150--0.556)   0.448   0.091                 0.667      0.641 (0.429--0.853)   0.621   0.455   0.722
  RFENB-nb                                0.202 (0.031--0.372)   0.310   0.091                 0.444      0.545 (0.293--0.797)   0.690   0.545   0.778
  RFENB-knn                               0.240 (0.049--0.430)   0.483   0.182                 0.667      0.556 (0.341--0.770)   0.621   0.545   0.667
  RFENB-lasso                             0.242 (0.065--0.419)   0.345   0.000                 0.556      0.530 (0.293--0.767)   0.552   0.273   0.722
  SBFLDA-lda                              0.621 (0.418--0.824)   0.621   0.727                 0.556      0.596 (0.355--0.836)   0.655   0.455   0.778
  SBFLDA-RF                               0.338 (0.139--0.536)   0.310   0.000                 0.500      0.722 (0.508--0.935)   0.793   0.636   0.889
  SBFLDA-svmLinear                        0.465 (0.254--0.674)   0.448   0.273                 0.556      0.616 (0.392--0.840)   0.655   0.455   0.778
  SBFLDA-svmRadial                        0.268 (0.086--0.448)   0.310   0.000                 0.500      0.545 (0.297--0.793)   0.655   0.273   0.889
  SBFLDA-nnet                             0.475 (0.263--0.686)   0.448   0.364                 0.500      0.707 (0.485--0.928)   0.759   0.545   0.889
  SBFLDA-nb                               0.434 (0.220--0.647)   0.448   0.455                 0.444      0.576 (0.333--0.818)   0.690   0.545   0.778
  SBFLDA-knn                              0.235 (0.072--0.396)   0.345   0.091                 0.500      0.619 (0.408--0.829)   0.655   0.545   0.722
  SBFLDA-lasso                            0.485 (0.264--0.704)   0.379   0.182                 0.500      0.571 (0.329--0.811)   0.621   0.455   0.722
  lasso-lda                               0.424 (0.215--0.633)   0.345   0.091                 0.500      0.505 (0.282--0.727)   0.552   0.455   0.611
  Table S1 (*continued*)                                                                                                                         

  Table S1 (*continued*)                                                                                            
  ------------------------ ---------------------- ------- ------- ------- -- ---------------------- ------- ------- -------
  lasso-RF                 0.298 (0.111--0.484)   0.379   0.000   0.611      0.568 (0.345--0.791)   0.552   0.182   0.778
  lasso-svmLinear          0.348 (0.151--0.545)   0.345   0.091   0.500      0.636 (0.429--0.842)   0.483   0.364   0.556
  lasso-svmRadial          0.394 (0.189--0.597)   0.379   0.273   0.444      0.606 (0.380--0.831)   0.448   0.273   0.556
  lasso-nnet               0.465 (0.254--0.675)   0.414   0.364   0.444      0.551 (0.331--0.769)   0.448   0.182   0.611
  lasso-nb                 0.331 (0.124--0.536)   0.414   0.182   0.556      0.455 (0.228--0.680)   0.483   0.273   0.611
  lasso-knn                0.399 (0.186--0.611)   0.448   0.091   0.667      0.576 (0.327--0.824)   0.552   0.455   0.611
  lasso-lasso              0.374 (0.168--0.579)   0.345   0.091   0.500      0.561 (0.346--0.774)   0.448   0.273   0.556

###### 

Result of Delong's test for AUCs of cross-combination statistical methods (AUC\>0.600)

  Cross-combination statistical methods   AUC (95% CI)           Z       P
  --------------------------------------- ---------------------- ------- -------
  Late arterial phase                                                    
  　SBFLDA-lda                            0.621 (0.418--0.824)   0.732   0.464
  Portal venous phase                                                    
  　lasso-svmLinear                       0.636 (0.429--0.842)   1.295   0.196
  　lasso-svmRadial                       0.606 (0.380--0.831)   0.923   0.356
  　RFERF-svmRadial                       0.626 (0.411--0.841)   1.151   0.250
  　RFERF-nnet                            0.606 (0.387--0.824)   0.952   0.341
  　RFERF-nb                              0.611 (0.341--0.880)   0.807   0.419
  　RFENB-lda                             0.631 (0.394--0.868)   1.086   0.278
  　RFENB-RF                              0.609 (0.388--0.829)   0.965   0.334
  　RFENB-nnet                            0.641 (0.429--0.853)   1.308   0.191
  　SBFLDA-RF                             0.722 (0.508--0.935)   2.039   0.041
  　SBFLDA-svmLinear                      0.616 (0.392--0.840)   1.016   0.310
  　SBFLDA-nnet                           0.707 (0.485--0.928)   1.832   0.067
  　SBFLDA-knn                            0.619 (0.408--0.829)   1.105   0.269

[^1]: \*These authors contributed equally to this article.
